Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation
Identifieur interne : 001477 ( Main/Corpus ); précédent : 001476; suivant : 001478Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation
Auteurs : Ioannis U. Isaias ; Riccardo Benti ; Stefano Goldwurm ; Michela Zini ; Roberto Cilia ; Paolo Gerundini ; Alessio Di Fonzo ; Vincenzo Bonifati ; Gianni Pezzoli ; Angelo AntoniniSource :
- Movement Disorders [ 0885-3185 ] ; 2006-08.
English descriptors
- KwdEn :
Abstract
We measured striatal dopamine transporter binding using [123I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2‐PD) and in gene‐negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2‐PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [123I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2‐PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between‐group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20909
Links to Exploration step
ISTEX:E75F3C323A113D564EB1DB2F1194C8C759F927A5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation</title><author><name sortKey="Isaias, Ioannis U" sort="Isaias, Ioannis U" uniqKey="Isaias I" first="Ioannis U." last="Isaias">Ioannis U. Isaias</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Benti, Riccardo" sort="Benti, Riccardo" uniqKey="Benti R" first="Riccardo" last="Benti">Riccardo Benti</name><affiliation><mods:affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Goldwurm, Stefano" sort="Goldwurm, Stefano" uniqKey="Goldwurm S" first="Stefano" last="Goldwurm">Stefano Goldwurm</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zini, Michela" sort="Zini, Michela" uniqKey="Zini M" first="Michela" last="Zini">Michela Zini</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Cilia, Roberto" sort="Cilia, Roberto" uniqKey="Cilia R" first="Roberto" last="Cilia">Roberto Cilia</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Gerundini, Paolo" sort="Gerundini, Paolo" uniqKey="Gerundini P" first="Paolo" last="Gerundini">Paolo Gerundini</name><affiliation><mods:affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Di Fonzo, Alessio" sort="Di Fonzo, Alessio" uniqKey="Di Fonzo A" first="Alessio" last="Di Fonzo">Alessio Di Fonzo</name><affiliation><mods:affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro Dino Ferrari, Department of Neurological Sciences, University of Milan, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name><affiliation><mods:affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurological Sciences, “La Sapienza” University, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E75F3C323A113D564EB1DB2F1194C8C759F927A5</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20909</idno><idno type="url">https://api.istex.fr/document/E75F3C323A113D564EB1DB2F1194C8C759F927A5/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001477</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation</title><author><name sortKey="Isaias, Ioannis U" sort="Isaias, Ioannis U" uniqKey="Isaias I" first="Ioannis U." last="Isaias">Ioannis U. Isaias</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Benti, Riccardo" sort="Benti, Riccardo" uniqKey="Benti R" first="Riccardo" last="Benti">Riccardo Benti</name><affiliation><mods:affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Goldwurm, Stefano" sort="Goldwurm, Stefano" uniqKey="Goldwurm S" first="Stefano" last="Goldwurm">Stefano Goldwurm</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zini, Michela" sort="Zini, Michela" uniqKey="Zini M" first="Michela" last="Zini">Michela Zini</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Cilia, Roberto" sort="Cilia, Roberto" uniqKey="Cilia R" first="Roberto" last="Cilia">Roberto Cilia</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Gerundini, Paolo" sort="Gerundini, Paolo" uniqKey="Gerundini P" first="Paolo" last="Gerundini">Paolo Gerundini</name><affiliation><mods:affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Di Fonzo, Alessio" sort="Di Fonzo, Alessio" uniqKey="Di Fonzo A" first="Alessio" last="Di Fonzo">Alessio Di Fonzo</name><affiliation><mods:affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Centro Dino Ferrari, Department of Neurological Sciences, University of Milan, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name><affiliation><mods:affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurological Sciences, “La Sapienza” University, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-08">2006-08</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1144">1144</biblScope><biblScope unit="page" to="1147">1147</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E75F3C323A113D564EB1DB2F1194C8C759F927A5</idno><idno type="DOI">10.1002/mds.20909</idno><idno type="ArticleID">MDS20909</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Gly2019Ser mutation</term><term>LRRK2</term><term>PARK8</term><term>[123I]ioflupane SPECT</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We measured striatal dopamine transporter binding using [123I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2‐PD) and in gene‐negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2‐PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [123I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2‐PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between‐group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ioannis U. Isaias MD</name><affiliations><json:string>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</json:string><json:string>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</json:string><json:string>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</json:string></affiliations></json:item><json:item><name>Riccardo Benti MD</name><affiliations><json:string>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</json:string></affiliations></json:item><json:item><name>Stefano Goldwurm MD</name><affiliations><json:string>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Michela Zini MD</name><affiliations><json:string>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</json:string><json:string>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</json:string></affiliations></json:item><json:item><name>Roberto Cilia MD</name><affiliations><json:string>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</json:string><json:string>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</json:string></affiliations></json:item><json:item><name>Paolo Gerundini MD</name><affiliations><json:string>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</json:string></affiliations></json:item><json:item><name>Alessio Di Fonzo MD</name><affiliations><json:string>Erasmus MC Rotterdam, Rotterdam, The Netherlands</json:string><json:string>Centro Dino Ferrari, Department of Neurological Sciences, University of Milan, Milan, Italy</json:string></affiliations></json:item><json:item><name>Vincenzo Bonifati MD</name><affiliations><json:string>Erasmus MC Rotterdam, Rotterdam, The Netherlands</json:string><json:string>Department of Neurological Sciences, “La Sapienza” University, Rome, Italy</json:string></affiliations></json:item><json:item><name>Gianni Pezzoli MD</name><affiliations><json:string>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Angelo Antonini MD</name><affiliations><json:string>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>[123I]ioflupane SPECT</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>LRRK2</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PARK8</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Gly2019Ser mutation</value></json:item></subject><articleId><json:string>MDS20909</json:string></articleId><language><json:string>eng</json:string></language><abstract>We measured striatal dopamine transporter binding using [123I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2‐PD) and in gene‐negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2‐PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [123I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2‐PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between‐group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society</abstract><qualityIndicators><score>4.743</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1223</abstractCharCount><pdfWordCount>2511</pdfWordCount><pdfCharCount>16395</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>186</abstractWordCount></qualityIndicators><title>Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation</title><genre><json:string>article</json:string></genre><host><volume>21</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>1147</last><first>1144</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.20909</json:string></doi><id>E75F3C323A113D564EB1DB2F1194C8C759F927A5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E75F3C323A113D564EB1DB2F1194C8C759F927A5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E75F3C323A113D564EB1DB2F1194C8C759F927A5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E75F3C323A113D564EB1DB2F1194C8C759F927A5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation</title><author><persName><forename type="first">Ioannis U.</forename><surname>Isaias</surname></persName><roleName type="degree">MD</roleName><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</affiliation><affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</affiliation></author><author><persName><forename type="first">Riccardo</forename><surname>Benti</surname></persName><roleName type="degree">MD</roleName><affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</affiliation></author><author><persName><forename type="first">Stefano</forename><surname>Goldwurm</surname></persName><roleName type="degree">MD</roleName><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Michela</forename><surname>Zini</surname></persName><roleName type="degree">MD</roleName><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</affiliation></author><author><persName><forename type="first">Roberto</forename><surname>Cilia</surname></persName><roleName type="degree">MD</roleName><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</affiliation></author><author><persName><forename type="first">Paolo</forename><surname>Gerundini</surname></persName><roleName type="degree">MD</roleName><affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</affiliation></author><author><persName><forename type="first">Alessio</forename><surname>Di Fonzo</surname></persName><roleName type="degree">MD</roleName><affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</affiliation><affiliation>Centro Dino Ferrari, Department of Neurological Sciences, University of Milan, Milan, Italy</affiliation></author><author><persName><forename type="first">Vincenzo</forename><surname>Bonifati</surname></persName><roleName type="degree">MD</roleName><affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</affiliation><affiliation>Department of Neurological Sciences, “La Sapienza” University, Rome, Italy</affiliation></author><author><persName><forename type="first">Gianni</forename><surname>Pezzoli</surname></persName><roleName type="degree">MD</roleName><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Angelo</forename><surname>Antonini</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Centro Parkinson, Istituti Clinici di Perfezionamento, 20126 Milan, Italy</p></note><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-08"></date><biblScope unit="volume">21</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1144">1144</biblScope><biblScope unit="page" to="1147">1147</biblScope></imprint></monogr><idno type="istex">E75F3C323A113D564EB1DB2F1194C8C759F927A5</idno><idno type="DOI">10.1002/mds.20909</idno><idno type="ArticleID">MDS20909</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We measured striatal dopamine transporter binding using [123I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2‐PD) and in gene‐negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2‐PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [123I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2‐PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between‐group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>[123I]ioflupane SPECT</term></item><item><term>LRRK2</term></item><item><term>PARK8</term></item><item><term>Gly2019Ser mutation</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-10-29">Received</change><change when="2005-12-12">Registration</change><change when="2006-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E75F3C323A113D564EB1DB2F1194C8C759F927A5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v21:8</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2006-08">August 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="150" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20909</doi><idGroup><id type="unit" value="MDS20909"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-10-29"></event><event type="manuscriptRevised" date="2005-11-22"></event><event type="manuscriptAccepted" date="2005-12-12"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-05-02"></event><event type="firstOnline" date="2006-05-02"></event><event type="publishedOnlineFinalForm" date="2006-08-22"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1144</numbering><numbering type="pageLast">1147</numbering></numberingGroup><correspondenceTo>Centro Parkinson, Istituti Clinici di Perfezionamento, 20126 Milan, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20909.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="2912"></count></countGroup><titleGroup><title type="main" xml:lang="en">Striatal dopamine transporter binding in Parkinson's disease associated with the <i>LRRK2</i> Gly2019Ser mutation</title><title type="short" xml:lang="en">Striatal Dopamine Transporter Binding</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3"><personName><givenNames>Ioannis U.</givenNames><familyName>Isaias</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Riccardo</givenNames><familyName>Benti</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Stefano</givenNames><familyName>Goldwurm</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Michela</givenNames><familyName>Zini</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Roberto</givenNames><familyName>Cilia</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Paolo</givenNames><familyName>Gerundini</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af4 #af5"><personName><givenNames>Alessio</givenNames><familyName>Di Fonzo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af4 #af6"><personName><givenNames>Vincenzo</givenNames><familyName>Bonifati</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Gianni</givenNames><familyName>Pezzoli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Angelo</givenNames><familyName>Antonini</familyName><degrees>MD</degrees></personName><contactDetails><email>angelo3000@yahoo.com</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="NL" type="organization"><unparsedAffiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="IT" type="organization"><unparsedAffiliation>Centro Dino Ferrari, Department of Neurological Sciences, University of Milan, Milan, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurological Sciences, “La Sapienza” University, Rome, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">[<sup>123</sup>I]ioflupane SPECT</keyword><keyword xml:id="kwd2"><i>LRRK2</i></keyword><keyword xml:id="kwd3">PARK8</keyword><keyword xml:id="kwd4">Gly2019Ser mutation</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We measured striatal dopamine transporter binding using [<sup>123</sup>I]ioflupane and SPECT in patients with Parkinson's disease associated with the <i>LRRK2</i> (PARK8) Gly2019Ser gene mutation (LRRK2‐PD) and in gene‐negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2‐PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [<sup>123</sup>I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2‐PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between‐group values. We conclude that in these patients carrying the <i>LRRK2</i> Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Striatal Dopamine Transporter Binding</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Striatal dopamine transporter binding in Parkinson's disease associated with the</title></titleInfo><name type="personal"><namePart type="given">Ioannis U.</namePart><namePart type="family">Isaias</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</affiliation><affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Riccardo</namePart><namePart type="family">Benti</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stefano</namePart><namePart type="family">Goldwurm</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michela</namePart><namePart type="family">Zini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roberto</namePart><namePart type="family">Cilia</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><affiliation>Department of Neurology, University of Milano‐Bicocca, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paolo</namePart><namePart type="family">Gerundini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>IRCCS–Ospedale Maggiore, Institute of Nuclear Medicine, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alessio</namePart><namePart type="family">Di Fonzo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</affiliation><affiliation>Centro Dino Ferrari, Department of Neurological Sciences, University of Milan, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vincenzo</namePart><namePart type="family">Bonifati</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Erasmus MC Rotterdam, Rotterdam, The Netherlands</affiliation><affiliation>Department of Neurological Sciences, “La Sapienza” University, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gianni</namePart><namePart type="family">Pezzoli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Angelo</namePart><namePart type="family">Antonini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><description>Correspondence: Centro Parkinson, Istituti Clinici di Perfezionamento, 20126 Milan, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-08</dateIssued><dateCaptured encoding="w3cdtf">2005-10-29</dateCaptured><dateValid encoding="w3cdtf">2005-12-12</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">24</extent><extent unit="words">2912</extent></physicalDescription><abstract lang="en">We measured striatal dopamine transporter binding using [123I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2‐PD) and in gene‐negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2‐PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [123I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2‐PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between‐group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>[123I]ioflupane SPECT</topic><topic>LRRK2</topic><topic>PARK8</topic><topic>Gly2019Ser mutation</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1144</start><end>1147</end><total>4</total></extent></part></relatedItem><identifier type="istex">E75F3C323A113D564EB1DB2F1194C8C759F927A5</identifier><identifier type="DOI">10.1002/mds.20909</identifier><identifier type="ArticleID">MDS20909</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001477 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001477 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E75F3C323A113D564EB1DB2F1194C8C759F927A5
|texte= Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation
}}
| This area was generated with Dilib version V0.6.23. |  |